Skip to main content
Premium Trial:

Request an Annual Quote

Kinaxo Lands $1.4M From German Gov't to Develop Small-Molecule Quantification Tool

NEW YORK (GenomeWeb News) — Kinaxo Biotechnologies has received around €1 million (approximately $1.4 million) from the German Ministry for Education and Research to develop a “universally applicable” chemical proteomics tool, the company said Monday.
The company said it plans to use the platform to “quantify small molecule-protein interactions in mammalian tissues and cell lines.”
Kinaxo’s head of research, Klaus Godl, said the company will use the funds to combine mass spectrometry with its KinaTor technology, in order to distinguish relevant drug-protein interactions from weak binding as well as determine a “compound’s affinity without the need of in vitro assays.”
These technologies are to be developed with help from Lothar Jänsch of the Helmholtz Institute and Henrik Daub of the Max Planck Institute.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.